Fig. 3From: Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: real-world results from a single academic center in AustriaOverall survival analysis. Number at risk: 3 months: 16(0), 6 months: 14 (1), 9 months: 5 (5), 12 months: 3 (6)Back to article page